By Matthias Blamont and Noëlle Mennella PARIS (Reuters) – Sanofi said it expected stable earnings per share this year after reporting lower fourth-quarter income on Tuesday, hurt by declining sales of diabetes and cancer treatments and other prescription drugs. The French drugmaker, which is in the midst of a reorganisation to address falling sales of its best-selling insulin drug Lantus, said sales of its next-generation insulin treatment Toujeo launched last year doubled in the fourth quarter compared with the previous three months. Shares in Sanofi were 0.4 percent lower at 69.6 euros at 0856 GMT, off 11 percent this year and down 25 percent since the company said in November its reorganisation would prevent any meaningful profit growth over the next two years.
Read the original post:
Sanofi pledges stable 2016 earnings